Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar

References

• WeyckerDBarronREdelsbergJKartashovALeggJGlassAGRisk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxisBMC Health Serv Res20141418924767095
   PubMed Web of Science ®Google Scholar
• BennettCLDjulbegovicBNorrisLBArmitageJOColony-stimulating factors for febrile neutropenia during cancer therapyN Engl J Med2013368121131113923514290
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkClinical practice guidelines in oncology (NCCN guidelines). Prevention and treatment of cancer-related infections2017 Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed June 19, 2017
   Google Scholar
• CulakovaEThotaRPoniewierskiMSPatterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort studyCancer Med20143243444424706592
   PubMed Web of Science ®Google Scholar
• KudererNMDaleDCCrawfordJCoslerLELymanGHMortality, morbidity, and cost associated with febrile neutropenia in adult cancer patientsCancer2006106102258226616575919
   PubMed Web of Science ®Google Scholar
• DulisseBLiXGayleJAA retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropeniaJ Med Econ201316672073523452298
   PubMedGoogle Scholar
• MichelsSLBarronRLReynoldsMWSmoyer TomicKYuJLymanGHCosts associated with febrile neutropenia in the USPharmacoeconomics201230980982322804805
   PubMed Web of Science ®Google Scholar
• LymanGHDaleDCCrawfordJIncidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practicesJ Clin Oncol200321244524453114673039
   PubMed Web of Science ®Google Scholar
• ShayneMCrawfordJDaleDCCulakovaELymanGHPredictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapyBreast Cancer Res Treat2006100325526216705366
   PubMed Web of Science ®Google Scholar
• LymanGHDaleDCCulakovaEThe impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trialsAnn Oncol201324102475248423788754
   PubMed Web of Science ®Google Scholar
• WildiersHReiserMRelative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphomaCrit Rev Oncol Hematol201177322124020227889
   PubMed Web of Science ®Google Scholar
• KudererNMDaleDCCrawfordJLymanGHImpact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic reviewJ Clin Oncol200725213158316717634496
   PubMed Web of Science ®Google Scholar
• Vanderpuye-OrgleJSexton WardAHuberCKamsonCJenaABEstimating the social value of G-CSF therapies in the United StatesAm J Manag Care20162210e343e34928557522
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkClinical practice guidelines in oncology (NCCN guidelines). Myeloid growth factors2017 Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed June 19, 2017
   Google Scholar
• SmithTJBohlkeKLymanGHRecommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline updateJ Clin Oncol201533283199321226169616
   PubMed Web of Science ®Google Scholar
• AaproMSBohliusJCameronDA2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursEur J Cancer 20112011471832
   Google Scholar
• PotoskyALMalinJLKimBUse of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomesJ Natl Cancer Inst20111031297998221670423
   PubMed Web of Science ®Google Scholar
• MulcahyAWPredmoreZMattkeSThe cost savings potential of biosimilar drugs in the United States2014 Available from: https://www.rand.org/content/dam/rand/pubs/perspectives/PE100/PE127/RAND_PE127.pdfAccessed July 12, 2017
   Google Scholar
• RaedlerLAZarxio (filgrastim-sndz): first biosimilar approved in the United StatesAm Health Drug Benefits20169Spec Feature15015427668063
   PubMedGoogle Scholar
• GascónPAaproMLudwigHTreatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)Support Care Cancer201624291192526306517
   PubMed Web of Science ®Google Scholar
• AaproMCornesPAbrahamIComparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropeniaJ Oncol Pharm Pract201218217117921610020
   PubMedGoogle Scholar
• McbrideACampbellKBikkinaMMacdonaldKAbrahamIBaluSCost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropeniaJ Med Econ201720101083109328722494
   PubMed Web of Science ®Google Scholar
• SchwartzbergLSLalLSBaluSClinical outcomes of treatment with filgrastim versus a filgrastim biosimilar and febrile neutropenia-associated costs among patients with nonmyeloid cancer undergoing chemotherapyJ Manag Care Spec Pharm201819
   Web of Science ®Google Scholar
• DouglasAGSchwabPLaneDKennedyKSlabaughSLBoweAA comparison of brand and biosimilar granulocyte-colony stimulating factors for prophylaxis of chemotherapy-induced febrile neutropeniaJ Manag Care Spec Pharm201723121221122629172983
   PubMed Web of Science ®Google Scholar
• CrawfordJDaleDCKudererNMRisk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practiceJ Natl Compr Canc Netw20086210911818319047
   PubMedGoogle Scholar
• QuanHLiBCourisCMUpdating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countriesAm J Epidemiol2011173667668221330339
   PubMed Web of Science ®Google Scholar
• NaeimAHenkHJBeckerLPegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)BMC Cancer2013131123298389
   PubMed Web of Science ®Google Scholar
• WeyckerDSofryginOSeefeldKDeeterRGLeggJEdelsbergJTechnical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databasesBMC Health Serv Res2013136023406481
   PubMed Web of Science ®Google Scholar
• AustinPCAn introduction to propensity score methods for reducing the effects of confounding in observational studiesMultivariate Behav Res201146339942421818162
   PubMed Web of Science ®Google Scholar
• KaplanELMeierPNonparametric estimation from incomplete observationsJ Am Stat Assoc195853282457481
   Web of Science ®Google Scholar
• WalkerENowackiASUnderstanding equivalence and noninferiority testingJ Gen Intern Med201126219219620857339
   PubMed Web of Science ®Google Scholar
• BlackwellKSemiglazovVKrasnozhonDComparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapyAnn Oncol20152691948195326122726
   PubMed Web of Science ®Google Scholar
• WeyckerDMalinJKimJRisk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort studyClin Ther20093151069108119539108
   PubMed Web of Science ®Google Scholar
• WeyckerDMalinJBarronREdelsbergJKartashovAOsterGComparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapyAm J Clin Oncol201235326727421378538
   PubMed Web of Science ®Google Scholar
• TanHTomicKHurleyDDanielGBarronRMalinJComparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective studyCurr Med Res Opin2011271798621091127
   PubMed Web of Science ®Google Scholar
• SmithTJKhatcheressianJLymanGH2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guidelineJ Clin Oncol200624193187320516682719
   PubMed Web of Science ®Google Scholar
• Zarxio (filgrastim-sndz) injection [prescribing information] Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe707775-a0ae-41b5-a744-28c41889fce8Accessed June 19, 2017
   Google Scholar
• AaproMCrawfordJKamionerDProphylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?Support Care Cancer201018552954120191292
   PubMed Web of Science ®Google Scholar
• WeyckerDLiXTzivelekisSBurden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with colony-stimulating factorSupport Care Cancer201725243944727734153
   PubMed Web of Science ®Google Scholar
• BokemeyerCGascónPAaproMOver- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF studySupport Care Cancer20172561819182828111718
   PubMed Web of Science ®Google Scholar
• WeyckerDHackettJEdelsbergJSOsterGGlassAGAre shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?Ann Pharmacother200640340240716492793
   PubMed Web of Science ®Google Scholar
• StantonDBiosimilars land in US and Sandoz launches Zarxio2015 Available from: http://www.biopharma-reporter.com/Markets-Regulations/Biosimilars-land-in-the-US-as-Sandoz-launches-ZarxioAccessed July 12, 2017
   Google Scholar
• GascónPTeschHVerpoortKClinical experience with Zarzio® in Europe: what have we learned?Support Care Cancer201321102925293223903799
   PubMed Web of Science ®Google Scholar
• McbrideABaluSCampbellKBikkinaMMacdonaldKAbrahamIExpanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndzFuture Oncol201713252285229528870106
   PubMed Web of Science ®Google Scholar